Loading...
XWAR
PUR
Market cap13mUSD
Jul 25, Last price  
5.79PLN
1D
-0.17%
1Q
-36.72%
IPO
-64.70%
Name

Pure Biologics SA

Chart & Performance

D1W1MN
P/E
P/S
497.52
EPS
Div Yield, %
Shrs. gr., 5y
22.91%
Rev. gr., 5y
-60.22%
Revenues
95k
-85.65%
1,288,904981,8359,531,94416,752,765572,000254,000662,00095,000
Net income
-36m
L+35.35%
0000-12,105,000-13,071,000-26,372,000-35,694,000
CFO
-23m
L+33.79%
0005,334,578-1,353,000-24,035,000-17,387,000-23,262,000

Profile

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.
IPO date
Dec 11, 2018
Employees
96
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
95
-85.65%
662
160.63%
Cost of revenue
9,208
37,884
Unusual Expense (Income)
NOPBT
(9,113)
(37,222)
NOPBT Margin
Operating Taxes
769
Tax Rate
NOPAT
(9,113)
(37,991)
Net income
(35,694)
35.35%
(26,372)
101.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,861
BB yield
-45.38%
Debt
Debt current
86
1,096
Long-term debt
13,069
4,626
Deferred revenue
74
Other long-term liabilities
39
Net debt
9,549
3,443
Cash flow
Cash from operating activities
(23,262)
(17,387)
CAPEX
(176)
(5,758)
Cash from investing activities
391
15,345
Cash from financing activities
24,218
(1,876)
FCF
(6,457)
(42,569)
Balance
Cash
3,606
7,178
Long term investments
(4,899)
Excess cash
3,601
2,246
Stockholders' equity
(92,596)
18,297
Invested Capital
107,427
18,951
ROIC
ROCE
EV
Common stock shares outstanding
3,288
2,221
Price
12.64
-45.04%
23.00
-70.44%
Market cap
41,564
-18.64%
51,086
-70.44%
EV
51,113
54,529
EBITDA
(3,329)
(34,725)
EV/EBITDA
Interest
3,833
329
Interest/NOPBT